According to the NCI website tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.

EMEA (EPAR was last updated on 28/11/2019)

• Fotivda is a medicine for treating adults with advanced renal cell carcinoma (a kidney cancer).
• Fotivda may be used in previously untreated patients or in those whose disease has got worse despite treatment with another medicine working in a different way.

Link to European Medicines Agency (EMEA)

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki

VEGF Receptor